Another recent study revealed that IL‐24 administration increased the expression of the epithelial marker E‐Cadherin and suppressed Zeb1 in glioblastoma multiforme (GBM) cell lines, leading to increased sensitivity to temozolomide. The gene discussed is CDH1; the disease is glioblastoma.